1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Key Findings
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. SPINAL MUSCULAR ATROPHY TREATMENT MARKET BY TYPE
5.1. Introduction
5.2. Type 1
5.3. Type 2
5.4. Type 3
5.5. Type 4
6. SPINAL MUSCULAR ATROPHY TREATMENT MARKET BY DRUG
6.1. Introduction
6.2. Spinraza
6.3. Zolgensma
6.4. Evrysdi
6.5. Others
7. SPINAL MUSCULAR ATROPHY TREATMENT MARKET BY ADMINISTRATION
7.1. Introduction
7.2. Oral
7.3. Injection
8. SPINAL MUSCULAR ATROPHY TREATMENT MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Type
8.2.2. By Drug
8.2.3. By Administration
8.2.4. By Country
8.2.4.1. United States
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Type
8.3.2. By Drug
8.3.3. By Administration
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Type
8.4.2. By Drug
8.4.3. By Administration
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Type
8.5.2. By Drug
8.5.3. By Administration
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Israel
8.5.4.4. Others
8.6. Asia Pacific
8.6.1. By Type
8.6.2. By Drug
8.6.3. By Administration
8.6.4. By Country
8.6.4.1. Japan
8.6.4.2. China
8.6.4.3. India
8.6.4.4. South Korea
8.6.4.5. Indonesia
8.6.4.6. Thailand
8.6.4.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Cure SMA
10.2. Evrysdi
10.3. Biogen
10.4. Novartis
10.5. Zolgensma
10.6. Roche
10.7. Fierce Pharma
10.8. Spinraza
10.9. Cleveland Clinic
10.10. Aster DM Healthcare